Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts | Daré Bioscience (darebioscience.com)April 30, 2024/in News/by Jeffrey OliverDaré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts | Daré Bioscience (darebioscience.com) /wp-content/uploads/2019/07/dare_logo.svg 0 0 Jeffrey Oliver /wp-content/uploads/2019/07/dare_logo.svg Jeffrey Oliver2024-04-30 10:23:352024-06-18 12:32:54Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts